{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:50Z","timestamp":1793781890895,"version":"4.6.1"},"reference-count":28,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Perianal fistulising Crohn\u2019s disease (pfCD) can be somewhat treatment refractory. Higher infliximab trough levels (TLIs) may improve fistula healing rates; however, it remains unclear whether escalating infliximab therapy to meet higher TLI targets using proactive, or routine, therapeutic drug monitoring (TDM) improves outcomes. This randomised controlled trial aimed to assess whether infliximab therapy targeting higher TLIs guided by proactive TDM improves outcomes compared with standard therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Patients with active pfCD will be randomised 1:1 to either the proactive TDM arm or standard dosing arm and followed up for 54 weeks. Patients in the proactive TDM arm will have infliximab dosing optimised to target higher TLIs. The targets will be TLI \u2265 25 \u00b5g\/mL at week 2, \u2265 20 \u00b5g\/mL at week 6 and \u2265 10 \u00b5g\/mL during maintenance therapy. The primary objective will be fistula healing at week 32. Secondary objectives will include fistula healing, fistula closure, radiological fistula healing, patient-reported outcomes and economic costs up to 54 weeks. Patients in the standard dosing arm will receive conventional infliximab dosing not guided by TLIs (5 mg\/kg at weeks 0, 2 and 6, and 5 mg\/kg 8 weekly thereafter). Patients aged 18\u201380 years with pfCD with single or multiple externally draining complex perianal fistulas who are relatively na\u00efve to infliximab treatment will be included. Patients with diverting ileostomies or colostomies and pregnant or breast feeding will be excluded. Fifty-eight patients per arm will be required to detect a 25% difference in the primary outcome measure, with 138 patients needed to account for an estimated 6.1% primary non-response rate and 10% dropout rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Results will be presented in peer-reviewed journals and international conferences. Ethics approval has been granted by the South Western Sydney Local Health District Human Research Ethics Committee in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry (ACTRN12621000023853); Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-043921","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T12:37:14Z","timestamp":1625143034000},"page":"e043921","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Prospective randomised controlled trial of adults with perianal fistulising Crohn\u2019s disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-1854","authenticated-orcid":false,"given":"Bonita","family":"Gu","sequence":"first","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"De Gregorio","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Gastroenterology and Hepatology, St Vincent\"s Hospital Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-918X","authenticated-orcid":false,"given":"Joseph Louis","family":"Pipicella","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia"},{"name":"Biostatistics Unit, The Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia"},{"name":"Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Begun","sequence":"additional","affiliation":[{"name":"Immunity, Infection, and Inflammation Program, Mater Research Institute, Brisbane, Queensland, Australia"},{"name":"Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Connell","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, St Vincent\"s Hospital Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, St Vincent\u2019s Hospital Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Gholamrezaei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia"},{"name":"Biostatistics Unit, The Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Diseases Unit, St Mark\"s Hospital, Harrow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Radford-Smith","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal Brisbane and Women\"s Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Department of Radiology, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Medical Imaging Department, St Vincent\"s Hospital Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Toong","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Immunology, NSW Health Pathology, Liverpool Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Woods","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, St Vincent\u2019s Hospital Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xuan","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Biostatistics Unit, The Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid-Jane","family":"Williams","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watson","family":"Ng","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Sheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Gastroenterology and Hepatology, St Vincent\"s Hospital Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Connor","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2025121510535158000_11.7.e043921.1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.5.696"},{"key":"2025121510535158000_11.7.e043921.2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32362"},{"key":"2025121510535158000_11.7.e043921.3","doi-asserted-by":"publisher","DOI":"10.1007\/BF02587272"},{"key":"2025121510535158000_11.7.e043921.4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/apt.14599","article-title":"Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease","volume":"47","author":"Vollebregt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121510535158000_11.7.e043921.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314918"},{"key":"2025121510535158000_11.7.e043921.6","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.3748\/wjg.v24.i42.4821","article-title":"Burden and outcomes for complex perianal fistulas in Crohn\"s disease: systematic review","volume":"24","author":"Panes","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025121510535158000_11.7.e043921.7","doi-asserted-by":"crossref","DOI":"10.4291\/wjgp.v5.i3.205","article-title":"Pathophysiology of fistula formation in Crohn\"s disease","volume":"5","author":"Scharl","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"2025121510535158000_11.7.e043921.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"2025121510535158000_11.7.e043921.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"2025121510535158000_11.7.e043921.10","doi-asserted-by":"crossref","first-page":"S053","DOI":"10.1093\/ecco-jcc\/jjy222.079","article-title":"DOP45 Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn\u2019s disease: a post-hoc analysis of the ACCENT-2 trial","volume":"13","author":"Vande Casteele","year":"2019","journal-title":"Journal of Crohn\u2019s colitis"},{"key":"2025121510535158000_11.7.e043921.11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab Trough levels are associated with perianal fistula healing in patients with Crohn\"s disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121510535158000_11.7.e043921.12","first-page":"549","article-title":"Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease","volume":"11","author":"Davidov","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2025121510535158000_11.7.e043921.13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MEG.0000000000001561","article-title":"Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn\"s disease","volume":"32","author":"Plevris","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025121510535158000_11.7.e043921.14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn\"s Disease","volume":"154","author":"D\"Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"2025121510535158000_11.7.e043921.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"2025121510535158000_11.7.e043921.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"2025121510535158000_11.7.e043921.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.07.027"},{"key":"2025121510535158000_11.7.e043921.18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clinimag.2019.10.007","article-title":"Evaluation of the modified van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn\"s disease","volume":"59","author":"van Rijn","year":"2020","journal-title":"Clin Imaging"},{"key":"2025121510535158000_11.7.e043921.19","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90585-1"},{"key":"2025121510535158000_11.7.e043921.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315503"},{"key":"2025121510535158000_11.7.e043921.21","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/ibd\/izy202","article-title":"Development of a sexual dysfunction scale for women with inflammatory bowel disease","volume":"24","author":"de Silva","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025121510535158000_11.7.e043921.22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/ibd\/izx053","article-title":"Sexual dysfunction in men with inflammatory bowel disease: a new IBD-specific scale","volume":"24","author":"O\"Toole","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025121510535158000_11.7.e043921.23","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121510535158000_11.7.e043921.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.02.016"},{"key":"2025121510535158000_11.7.e043921.25","unstructured":"Pharmaceutical Benefits Scheme . Crohn\u2019s disease: adalimumab and infliximab In: (DUSC) Dus-c, editor. Public Release Document, 2015."},{"key":"2025121510535158000_11.7.e043921.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121510535158000_11.7.e043921.27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther Drug Monit"},{"key":"2025121510535158000_11.7.e043921.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204769"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-043921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:53:58Z","timestamp":1765824838000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-043921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bmjopen-2020-043921"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-043921","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}